Nasal High Flow Therapy 30 Day Readmission Study
Status: | Terminated |
---|---|
Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/28/2018 |
Start Date: | November 2015 |
End Date: | May 3, 2017 |
Nasal High Flow (NHF) Therapy Use Following Hospitalization for an Exacerbation of COPD: A Feasibility Study
The aim of this feasibility study is to provide data for a subsequent randomized controlled
trial to investigate if patient outcomes will be improved after an acute COPD exacerbation
using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility
study will investigate the following: process, resources, management and scientific aspects
of delivering NHF as an adjunct therapy in COPD patients.
trial to investigate if patient outcomes will be improved after an acute COPD exacerbation
using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility
study will investigate the following: process, resources, management and scientific aspects
of delivering NHF as an adjunct therapy in COPD patients.
Inclusion Criteria:
- 18 years of age or older
- Male and female
- Admitted to the respiratory ward(s) of either recruiting hospitals with AECOPD as the
primary diagnostic reason for admission.
Exclusion Criteria:
- Given a new home oxygen therapy prescription during the current hospital admission
- The investigator believes the participant or their care giver will be unable to safely
use the myAIRVO 2 device following discharge
- They have any other condition which, at the investigator's discretion, is believed may
present a safety risk or impact the feasibility of the study or the study results
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials